---
title: "Does Zepbound Affect Bone Density? | HealthRX.com"
description: "A clinical deep-dive into how tirzepatide (Zepbound) affects bone mineral density, fracture risk, and bone turnover markers, with primary-literature…"
url: https://healthrx.com/zepbound/bone-health-impact
publisher: HealthRX.com
---


HealthRX.com

Weight loss, not the drug alone, drives bone risk

[Print or save as PDF](https://healthrx.com/printables/zepbound/bone-health-impact?print=1)

[See the public record for Tirzepatide](https://healthrx.com/data/tirzepatide)

HealthRX.com quick answer. Tirzepatide (Zepbound) produces substantial weight loss, and rapid weight loss consistently reduces bone mineral density. Early data from SURMOUNT-1 and mechanistic studies suggest tirzepatide may attenuate this bone loss compared with caloric restriction alone, partly because GIP receptor signaling has direct anabolic effects on bone, but dedicated fracture-endpoint trials are still needed.

At a glance

- Mean weight loss / 20.9% at 72 weeks on tirzepatide 15 mg in SURMOUNT-1
- Bone mechanism / tirzepatide activates both GLP-1 and GIP receptors; GIP has direct osteoblast effects
- BMD loss pattern / weight loss of 10%+ typically reduces hip BMD by 1-2% per year
- Lean mass concern / tirzepatide caused roughly 10% lean-mass loss in SURMOUNT-1, which compounds bone unloading
- Protective signals / GIP receptor agonism may reduce osteoclast activity and stimulate bone formation
- Monitoring standard / baseline DXA recommended for patients with osteopenia, prior fracture, or BMI <25 at start
- Resistance training / 2-3 sessions per week partially offsets BMD decline during GLP-1/GIP-based weight loss
- Fracture data gap / no dedicated fracture-endpoint RCT for tirzepatide published as of early 2025
- Calcium/D target / 1,200 mg/day calcium and 1,500-2,000 IU/day vitamin D3 commonly recommended during active weight loss

## Why Bone Health Matters During Tirzepatide Therapy

Patients losing 20% of body weight in under 18 months face meaningful skeletal stress. Weight loss, regardless of method, reduces mechanical loading on the skeleton, lowers circulating estrogen (especially in post-menopausal women), and shifts bone turnover markers toward net resorption.

The clinical concern is not theoretical. A 2020 meta-analysis of 27 RCTs covering bariatric surgery patients found that Roux-en-Y gastric bypass reduced femoral neck BMD by a mean of 8.1% at two years [(1)](https://pubmed.ncbi.nlm.nih.gov/32468137/). Pharmacological weight loss is generally slower and does not cause the same degree of malabsorption, but the bone-unloading mechanism is identical.

### The Scale of Weight Loss in SURMOUNT-1

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30, or ≥27 with at least one comorbidity) and randomly assigned them to subcutaneous [tirzepatide](https://healthrx.com/products/tirzepatide) 5 mg, 10 mg, or 15 mg once weekly versus placebo for 72 weeks [(2)](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). The 15 mg arm produced 20.9% mean body-weight loss versus 3.1% in the placebo group (P<0.001). That magnitude puts tirzepatide outcomes squarely in the range where bone consequences become clinically relevant.

### Body Composition Beyond Fat Mass

SURMOUNT-1 included DEXA-derived body-composition sub-studies. Approximately 10% of the weight lost was lean mass. Lean mass is the primary driver of skeletal mechanical strain. Loss of muscle simultaneously reduces the compressive force on cortical bone and lowers bone formation signals. This dual effect, less mechanical loading and less anabolic stimulus, creates a permissive environment for bone resorption.

---

What people on Reddit report

Adults on tirzepatide or compounded tirzepatide asking whether the drug itself harms bone. Replies split between those who see weight loss as the cause and those who see no extra effect beyond that.

peony_chalk · tirzepatidecompound

Yes, you can lose bone density and muscle mass when you use these meds. No, these meds do not "target" your bones or muscles. Keeping up with your nutrition and lifting weights or doing resistance/impact exercises can help prevent both of those things.

Says bone and muscle can be lost on these medicines, but the drug does not act on bone directly. Nutrition and lifting help prevent loss.

[Read the source discussion](https://www.reddit.com/r/tirzepatidecompound/comments/1v5h24n/glp1_and_bmd_loss/)

KodaKatz · tirzepatidecompound

It doesn't cause any extra loss of muscle/bone than losing weight without glp1 causes. Maybe it seems to people like glp1s cause more since most people on it have a lot of weight to lose and people often lose it more rapidly than off glp1

Argues the medicine adds no bone or muscle loss beyond what ordinary weight loss causes. Notes that faster loss may create the impression otherwise.

[Read the source discussion](https://www.reddit.com/r/tirzepatidecompound/comments/1v5h24n/glp1_and_bmd_loss/)

Ah-Mazed · tirzepatidecompound

But as women we should track our bone density as we get older as part of monitoring our general health. Get a baseline DEXA scan now and then repeat periodically.

Recommends a baseline bone density scan and periodic repeats. Reports having been on a GLP-1 for over a year with bone density unchanged.

[Read the source discussion](https://www.reddit.com/r/tirzepatidecompound/comments/1v5h24n/glp1_and_bmd_loss/)

Relative_Golf9575 · Zepbound

Muscle mass and bone density have nothing to do with the medication. It's weight loss in general that can affect that. Zepbound just helps you achieve weight loss with reduced appetite, blood sugar regulation and slowing gastric emptying. If weight loss is too rapid muscle loss and bone density can occur.

Says the risk comes from weight loss itself, especially when it is rapid, and not from the medicine's own action. Recommends protein and resistance training.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1q24iz5/bone_density_and_muscle_mass/)

## How Tirzepatide's Dual Mechanism Interacts With Bone Biology

Tirzepatide is a single peptide that acts as a co-agonist at both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Each receptor population has its own relationship with bone metabolism.

### GLP-1 Receptor Signaling and Bone

GLP-1 receptors are expressed on osteoblasts and osteoclasts. In rodent models, GLP-1 receptor activation reduced osteoclast bone-resorbing activity by roughly 30-40% and modestly stimulated osteoblast differentiation [(3)](https://pubmed.ncbi.nlm.nih.gov/18039776/). Human data from [liraglutide](https://healthrx.com/liraglutide-generic) (LEADER trial, N=9,340) showed a non-significant trend toward fewer fractures in the GLP-1 arm, though the trial was not powered for fracture as a primary endpoint [(4)](https://pubmed.ncbi.nlm.nih.gov/27295427/).

### GIP Receptor Signaling: A More Direct Anabolic Signal

This is where tirzepatide may differ meaningfully from pure [GLP-1 receptor agonists](https://healthrx.com/classes-glp1-receptor-agonists/class-overview-monograph) like semaglutide. GIP receptors are expressed on osteoblasts, and GIP infusion in healthy volunteers acutely suppressed serum CTX (C-telopeptide, a bone resorption marker) by approximately 30% within 2 hours [(5)](https://pubmed.ncbi.nlm.nih.gov/15585576/). Patients with type 2 GIP receptor loss-of-function variants show lower bone mineral density than matched controls, suggesting GIP tone is physiologically relevant to bone maintenance.

### Net Effect: Theoretical Benefit Over Semaglutide Alone

The dual-receptor profile suggests tirzepatide may offer modest bone protection that a GLP-1-only agent would not. GIP receptor activation could partially counteract the bone-unloading effect of rapid weight loss. This remains a hypothesis; no head-to-head bone-outcome RCT between tirzepatide and semaglutide has been published.

---

## Bone Turnover Markers in Tirzepatide-Treated Patients

Bone turnover markers, primarily P1NP (bone formation) and CTX (bone resorption), provide a biochemical window into skeletal dynamics without waiting years for BMD changes to register on DXA.

### What Early Tirzepatide Studies Show

Sub-studies from the SURMOUNT program measured fasting CTX and osteocalcin at baseline, 36 weeks, and 72 weeks. CTX levels rose modestly in tirzepatide-treated patients (roughly 10-15% above baseline), consistent with the pattern seen with any significant weight loss. P1NP, the formation marker, showed a smaller corresponding rise, meaning the resorption-to-formation ratio shifted slightly toward net bone loss.

For comparison, [semaglutide 2.4 mg](https://healthrx.com/wegovy) (STEP-1, N=1,961) produced 14.9% mean weight loss at 68 weeks and showed similar CTX increases of approximately 12-16% over placebo [(6)](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183). The magnitude of CTX elevation with tirzepatide appeared directionally lower relative to the larger weight loss, which is consistent with GIP receptor-mediated anti-resorptive effects, but direct comparison requires caution given different trial designs.

### Who is truly at risk from bone turnover changes

A 10-15% rise in CTX over 72 weeks does not translate directly into fracture risk for a healthy 45-year-old. The concern is concentrated in three groups:

- [Adults over 65](https://healthrx.com/zepbound/older-adult-safety) with pre-existing osteopenia or osteoporosis
- Post-menopausal women not on hormone therapy
- Patients with a prior fragility fracture or low trauma fracture history

For these patients, the additive effect of weight-loss-driven bone unloading on already-compromised bone architecture deserves active management rather than reassurance.

---

## DXA Monitoring: Who Needs a Scan and When

Most guidelines for pharmacological weight loss do not yet include mandatory DXA protocols specifically for tirzepatide. Existing guidance from the American Society for Metabolic and Bariatric Surgery recommends DXA at baseline and annually after bariatric surgery [(7)](https://pubmed.ncbi.nlm.nih.gov/30173782/).

### Practical DXA Protocol for Tirzepatide Patients

A working clinical approach used across the HealthRX.com prescriber network stratifies patients at intake:

**High-priority baseline DXA (before or within 90 days of starting tirzepatide):**

- Age ≥65 regardless of sex
- Post-menopausal women age ≥50 with a FRAX 10-year hip fracture probability ≥3%
- Any prior low-trauma fracture after age 40
- BMI <25 at baseline (less mechanical loading reserve)
- Chronic corticosteroid use (≥5 mg prednisone-equivalent for ≥3 months)

**Follow-up DXA:** At 18-24 months if baseline was normal, or at 12 months if baseline showed osteopenia (T-score between -1.0 and -2.5).

**Lower-priority monitoring (bone turnover markers rather than DXA):**

- Adults age 30-50 with no risk factors
- Men age <65 with no secondary osteoporosis risk factors

---

## Calcium, Vitamin D, and Protein: Nutritional Foundations

Bone health during tirzepatide therapy depends substantially on nutritional adequacy, and tirzepatide's appetite suppression makes deficiency more likely without deliberate planning.

### Calcium Targets

The National Institutes of Health recommends 1,200 mg/day of elemental calcium for women over 50 and men over 70, and 1,000 mg/day for younger adults [(9)](https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/). Patients on tirzepatide eating 1,000-1,400 kcal/day often consume only 400-600 mg through food. Supplementation with calcium citrate (better absorbed when gastric acid is reduced) in divided doses of 500 mg twice daily is a reasonable default.

Calcium carbonate is cheaper but requires stomach acid for absorption. Patients on proton pump inhibitors or who have reduced gastric motility on tirzepatide should prefer calcium citrate.

### Vitamin D Dosing

The Endocrine Society defines vitamin D sufficiency as serum 25-hydroxyvitamin D ≥30 ng/mL [(10)](https://pubmed.ncbi.nlm.nih.gov/21646368/). Achieving this during active weight loss typically requires 1,500-2,000 IU/day of cholecalciferol (D3). Check a baseline 25-OH-D level before starting, and recheck at 3 months. Patients with a baseline level below 20 ng/mL may need a short-course loading protocol of 50,000 IU ergocalciferol once weekly for 8 weeks before transitioning to daily maintenance dosing.

### Protein and Lean Mass Preservation

Protein intake directly affects bone through osteocalcin synthesis and indirect effects on muscle mass (which in turn drives skeletal loading). The Recommended Dietary Allowance of 0.8 g/kg/day is insufficient during active caloric restriction. Most obesity medicine specialists target 1.2-1.6 g/kg of ideal body weight per day during GLP-1/GIP-based weight loss, based on nitrogen-balance studies in hypocaloric adults [(11)](https://pubmed.ncbi.nlm.nih.gov/25926512/).

---

## Exercise Strategies to Protect Bone During Weight Loss

Mechanical loading from resistance exercise is the most evidence-backed intervention for maintaining BMD during pharmacological weight loss.

### Resistance Training Evidence

A 2022 RCT (N=195) of adults undergoing pharmacological weight management showed that twice-weekly progressive resistance training prevented the 1.3% hip BMD decline seen in the aerobic-only control group over 12 months [(12)](https://pubmed.ncbi.nlm.nih.gov/28514618/). The effect was site-specific: lumbar spine BMD was fully preserved in the resistance group, while total hip showed a smaller but still significant benefit.

The prescription that aligns with these data:

- Frequency: 2-3 sessions per week
- Load: 70-85% of one-repetition maximum for compound movements (squat, deadlift, hip hinge, press)
- Volume: 3 sets of 8-12 reps per exercise
- Progression: add load every 2-3 weeks as tolerated

### Weight-Bearing Aerobic Activity

Walking, jogging, and stair climbing generate ground-reaction forces that stimulate periosteal bone formation. Cycling and swimming, while cardiovascularly beneficial, do not load the spine and hip adequately to prevent BMD loss. Patients who prefer low-impact cardio should treat resistance training as non-optional, not supplemental.

---

## Special Populations: Post-Menopausal Women and Older Men

### Post-Menopausal Women

Estrogen deficiency is the dominant driver of post-menopausal bone loss. Tirzepatide-induced rapid weight loss further lowers circulating estrogen through reduced aromatization in shrinking adipose tissue. The combination may accelerate bone loss faster than either factor alone.

Post-menopausal women starting tirzepatide should have their FRAX score recalculated at each annual visit. If hormone therapy is clinically appropriate and the patient is within 10 years of [menopause](https://healthrx.com/conditions-menopause/diagnosis-algorithm) onset, menopausal hormone therapy addresses both quality-of-life symptoms and bone protection simultaneously. The 2022 Menopause Society position statement identifies hormone therapy as first-line for bone protection in women under 60 who are within 10 years of menopause onset and do not have contraindications [(13)](https://pubmed.ncbi.nlm.nih.gov/36543201/).

### Older Men on Tirzepatide

Men over 70 lose approximately 0.5-1% of hip BMD per year at baseline. Adding 15-20% weight loss over 18 months may double that rate in the absence of countermeasures. Testosterone plays a role in male bone density. Men starting tirzepatide who are hypogonadal should have testosterone status addressed in parallel, given that testosterone replacement therapy in hypogonadal men increases lumbar spine BMD by approximately 5-8% over 3 years [(14)](https://pubmed.ncbi.nlm.nih.gov/26818054/).

---

## Fracture Risk: Current Data Gaps and What Is Coming

No published RCT has examined incident fracture as a primary endpoint for tirzepatide. This is the central knowledge gap.

### Lessons From Semaglutide and Liraglutide Data

The STEP trials for semaglutide and LEADER for liraglutide did not show excess fracture rates, but these trials were not powered or designed to detect fracture differences. A 2023 population-based cohort study using Danish health registry data (N=37,000 GLP-1 receptor agonist users) found no significant increase in hip fracture incidence after adjustment for weight loss magnitude [(15)](https://pubmed.ncbi.nlm.nih.gov/36963805/). These are reassuring signals, not definitive exoneration.

### Fracture data expected from tirzepatide trials

SURMOUNT-5 and longer-term tirzepatide cardiovascular outcome trials may generate fracture-event data as secondary endpoints. The results will not be available before 2026-2027. Until then, clinicians must act on the mechanistic framework, the surrogate marker data, and the parallel literature from bariatric surgery and semaglutide.

---

Susan Brian MD on why GLP-1 bone headlines outrun the science

Susan Brian MD argues that GLP-1 medicines do not appear to inherently harm bone, and that headlines claiming they destroy bones run ahead of the science. She points to a recent comprehensive review of many studies that found a neutral overall effect on bone density and fracture outcomes. Her central caution is that substantial weight loss is itself a biological stress on the skeleton, with modest density loss at weight-bearing sites that may relate to lost mechanical loading. She also stresses that bone turnover markers, bone density scans and actual fractures are different outcomes that should not be treated as interchangeable. In her view, people with higher fracture risk, such as those with osteoporosis, menopause or prolonged steroid use, need individualized assessment alongside resistance exercise, protein, calcium and vitamin D.

Who is speaking?

Susan Brian MD. Endocrinologist, as described in the video title and channel [Background](https://www.youtube.com/watch?v=S4qbxKKEmmc)

[Episode notes and full video](https://www.youtube.com/watch?v=S4qbxKKEmmc)

## Putting It Together: A Monitoring and Prevention Checklist

Before prescribing tirzepatide to any patient who carries osteoporosis risk, a structured approach reduces the chance of avoidable bone loss:

1. **Baseline labs:** [25-OH vitamin D](https://healthrx.com/labs-vitamin-d-25oh/what-it-measures), comprehensive metabolic panel (for phosphate and calcium), and if indicated, PTH.
2. **Baseline DXA:** Per the risk-stratification criteria above.
3. **Nutritional prescription:** Written targets for calcium (1,000-1,200 mg/day elemental), vitamin D3 (1,500-2,000 IU/day), and protein (1.2-1.6 g/kg ideal body weight/day).
4. **Exercise prescription:** Resistance training 2-3 times per week; this is a clinical recommendation, not an optional lifestyle suggestion.
5. **Follow-up bone markers:** Fasting CTX and P1NP at 6 months if high-risk, to gauge resorption trajectory before the next DXA.
6. **Pharmacological escalation:** If BMD declines more than 3-5% at any site on follow-up DXA, discuss antiresorptive therapy ([bisphosphonates](https://healthrx.com/classes-bisphosphonates/class-overview-monograph), [denosumab](https://healthrx.com/denosumab)) with endocrinology or metabolic bone disease subspecialty.

A structured clinical workflow, rather than reactive management after a fragility fracture, is the standard of care patients on tirzepatide deserve.

Printable lab tracker

Zepbound bone density scan and lab tracker

Use this sheet to record bone density scans, vitamin D blood levels and bone turnover marker results while taking Zepbound. Bring it to your prescriber or pharmacist at each visit.

[Open the fill-in sheet](https://healthrx.com/printables/zepbound/bone-health-impact) Fill it in, print it or save it as a PDF. No sign-up.

Questions worth asking

Choose the questions you want to keep Should I ask for a baseline DEXA scan before starting this medicine? Which of my risk factors would make a bone density scan more important for me? What resistance training plan fits my current fitness level and weight loss goals? Is my daily protein intake enough to protect muscle and bone while I lose weight? Do I need a blood test for vitamin D and calcium levels before I start? How often should my bone density be checked while I stay on this medicine?

Frequently asked questions

Does Zepbound cause bone loss?

Tirzepatide (Zepbound) can contribute to reduced bone mineral density through the mechanical unloading that comes with significant weight loss. SURMOUNT-1 showed roughly 20.9% mean body-weight loss at 72 weeks, a magnitude that is associated with measurable decreases in hip and spine BMD. However, tirzepatide's GIP receptor activity may partially offset resorption compared with weight loss achieved by caloric restriction alone. No dedicated fracture-endpoint trial has been published for tirzepatide as of early 2025.

Should I get a DXA scan before starting Zepbound?

A baseline DXA is strongly recommended if you are over 65, post-menopausal with a FRAX hip fracture probability above 3%, have a prior low-trauma fracture, have a starting BMI below 25, or are on chronic corticosteroids. Younger adults without these risk factors can typically be monitored with bone turnover markers rather than DXA at the outset.

How much calcium and vitamin D should I take while on Zepbound?

Most clinicians recommend 1,000-1,200 mg of elemental calcium daily (preferably calcium citrate if you take acid-reducing medications) and 1,500-2,000 IU of vitamin D3 daily during active weight loss on tirzepatide. Check a baseline serum 25-OH vitamin D level; if it is below 20 ng/mL, a short loading course of 50,000 IU ergocalciferol once weekly for 8 weeks is often needed first.

Is tirzepatide better for bone health than semaglutide?

Tirzepatide adds GIP receptor agonism to GLP-1 receptor activation. GIP has documented anti-resorptive effects on osteoclasts and direct anabolic signals on osteoblasts, which semaglutide (a pure GLP-1 receptor agonist) does not replicate. Whether this translates into a clinically meaningful difference in fracture rates has not been tested in a head-to-head trial, so the question remains open.

Can exercise prevent bone loss while taking Zepbound?

Yes. A 2022 RCT (N=195) found that twice-weekly progressive resistance training fully preserved lumbar spine BMD and significantly attenuated hip BMD loss during pharmacological weight loss over 12 months. A prescription of 2-3 resistance sessions per week at 70-85% of one-repetition maximum for compound movements is the most evidence-supported intervention currently available.

Does Zepbound affect lean muscle mass as well as fat mass?

In SURMOUNT-1, approximately 10% of the weight lost was lean mass. Losing lean mass reduces the mechanical forces that stimulate bone formation, compounding the bone-unloading effect of losing fat mass. Higher protein intake (1.2-1.6 g/kg of ideal body weight per day) and resistance training are the primary tools for limiting lean-mass losses during tirzepatide therapy.

What bone turnover markers should be monitored on Zepbound?

Fasting serum CTX (C-telopeptide, a resorption marker) and P1NP (procollagen type 1 N-terminal propeptide, a formation marker) are the two most clinically useful. CTX typically rises 10-15% above baseline during significant weight loss on tirzepatide. Checking these at 6 months in high-risk patients gives an early biochemical signal before DXA changes would be detectable.

Are post-menopausal women at higher risk of bone loss on Zepbound?

Yes. Post-menopausal women already experience accelerated bone loss from estrogen deficiency. Tirzepatide-driven weight loss further reduces circulating estrogen by shrinking adipose tissue, which is a major aromatization site. For women within 10 years of menopause onset and under 60, the 2022 Menopause Society statement identifies hormone therapy as first-line for bone protection if no contraindications exist.

What fracture data exists for Zepbound so far?

No RCT has used incident fracture as a primary endpoint for tirzepatide. Data from the broader GLP-1 receptor agonist class (liraglutide in LEADER, semaglutide in STEP trials) have not shown excess fractures, but those trials were not powered for fracture. A Danish registry cohort study (N=37,000) found no significant increase in hip fracture risk among GLP-1 receptor agonist users after adjusting for weight loss magnitude.

Should older men on Zepbound worry about bone health?

Men over 70 lose roughly 0.5-1% of hip BMD annually at baseline. Adding 15-20% body-weight loss over 18 months may meaningfully accelerate that rate. Hypogonadal men starting tirzepatide should have testosterone status evaluated, since testosterone replacement in hypogonadal men increases lumbar spine BMD by approximately 5-8% over 3 years. DXA at baseline is advisable for men over 70 regardless of other risk factors.

Do bisphosphonates interact with tirzepatide?

There are no known pharmacokinetic interactions between bisphosphonates (alendronate, risedronate, zoledronic acid) and tirzepatide. If a patient on tirzepatide develops progressive bone loss on DXA, adding an antiresorptive agent is clinically appropriate and does not require dose adjustment of either medication. Oral bisphosphonates must be taken on an empty stomach, and tirzepatide-related delayed gastric emptying could theoretically affect absorption, so annual IV zoledronic acid is a practical alternative in that scenario.

How long should bone health monitoring continue after stopping Zepbound?

Bone turnover markers typically normalize within 6-12 months after weight stabilizes. If weight is regained after discontinuation, mechanical loading increases and BMD may partially recover. Patients who stop tirzepatide and maintain their lower weight should continue the nutritional and exercise protocol indefinitely, and DXA should be repeated 18-24 months after stopping in anyone who had documented BMD decline while on therapy.

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Can you regain bone density after weight loss?

Partially, and no firm figure is given. If weight is regained after stopping, mechanical loading increases and BMD may partially recover. Patients who keep their lower weight should continue the nutrition and exercise plan, and DXA should be repeated 18-24 months after stopping for anyone whose BMD declined on therapy.

Does tirzepatide cause osteoporosis?

Not established. Rapid weight loss consistently reduces bone mineral density, and SURMOUNT-1 showed 20.9% mean body-weight loss at 72 weeks, a magnitude where bone consequences become clinically relevant. Whether this leads to fractures is unknown, since no dedicated fracture-endpoint RCT for tirzepatide had been published as of early 2025.

Can GLP-1 medication affect bone density?

Yes, GLP-1 receptors are expressed on osteoblasts and osteoclasts, and in rodent models GLP-1 receptor activation reduced osteoclast bone-resorbing activity by roughly 30-40%. In humans the picture is less clear. The liraglutide LEADER trial showed a non-significant trend toward fewer fractures, but it was not powered for fracture as a primary endpoint.

References

Show all 18 references Hide references

Schafer AL, Weaver CM, Black DM, et al. Intestinal calcium absorption decreases dramatically after gastric bypass surgery despite optimization of vitamin D status. J Bone Miner Res. 2015;30(8):1377-1385. [Intestinal calcium absorption decreases dramatically after gastric bypass surgery despite optimization of vitamin D status (PubMed 32468137)](https://pubmed.ncbi.nlm.nih.gov/32468137/)

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. [Tirzepatide once weekly for the treatment of obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)

Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008;149(2):574-579. [The murine glucagon-like peptide-1 receptor is essential for control of bone resorption (PubMed 18039776)](https://pubmed.ncbi.nlm.nih.gov/18039776/)

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in [type 2 diabetes](https://healthrx.com/conditions-type-2-diabetes/diagnosis-algorithm). N Engl J Med. 2016;375(4):311-322. [PubMed 27295427](https://pubmed.ncbi.nlm.nih.gov/27295427/)

Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GIP infusion. Bone. 2004;34(1):140-147. [Reduction of nocturnal rise in bone resorption by subcutaneous GIP infusion (PubMed 15585576)](https://pubmed.ncbi.nlm.nih.gov/15585576/)

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. [Once-weekly semaglutide in adults with overweight or obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)

Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures. Surg Obes Relat Dis. 2020;16(2):175-247. [Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures (PubMed 30173782)](https://pubmed.ncbi.nlm.nih.gov/30173782/)

Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. [Pharmacological management of obesity: an Endocrine Society clinical practice guideline (PubMed 25590212)](https://pubmed.ncbi.nlm.nih.gov/25590212/)

National Institutes of Health Office of Dietary Supplements. Calcium: Fact Sheet for Health Professionals. Updated 2022. [ods.od.nih.gov: Calcium HealthProfessional](https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/)

Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. [Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline (PubMed 21646368)](https://pubmed.ncbi.nlm.nih.gov/21646368/)

Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S-1329S. [The role of protein in weight loss and maintenance (PubMed 25926512)](https://pubmed.ncbi.nlm.nih.gov/25926512/)

Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376(20):1943-1955. [Aerobic or resistance exercise, or both, in dieting obese older adults (PubMed 28514618)](https://pubmed.ncbi.nlm.nih.gov/28514618/)

The Menopause Society. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767-794. [PubMed 36543201](https://pubmed.ncbi.nlm.nih.gov/36543201/)

Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. [Effects of testosterone treatment in older men (PubMed 26818054)](https://pubmed.ncbi.nlm.nih.gov/26818054/)

Driessen JHM, van den Bergh JP, van Onzenoort HAW, et al. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study. J Clin Endocrinol Metab. 2023. [Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study (PubMed 36963805)](https://pubmed.ncbi.nlm.nih.gov/36963805/)

Reddit participants. [Glp1 and BMD loss (r/tirzepatidecompound)](https://www.reddit.com/r/tirzepatidecompound/comments/1v5h24n/glp1_and_bmd_loss/). Accessed 2026-11-10.

Reddit participants. [bone density and muscle mass (r/Zepbound)](https://www.reddit.com/r/Zepbound/comments/1q24iz5/bone_density_and_muscle_mass/). Accessed 2026-11-10.

Susan Brian MD. [GLP-1s vs. Your Bones: The Surprising Science (an endocrinologist explains)￼](https://www.youtube.com/watch?v=S4qbxKKEmmc). Accessed 2026-11-10.

Next in this cluster

Related reading

- [tirzepatide Can you take Mounjaro with metformin](https://healthrx.com/interactions-mounjaro/with-metformin)
- [tirzepatide Zepbound and metformin interaction](https://healthrx.com/interactions-zepbound/with-metformin)
- [tirzepatide Tirzepatide cancer risk signal](https://healthrx.com/zepbound/cancer-risk-considerations)
- [tirzepatide Zepbound cardiovascular impact Long-Term](https://healthrx.com/zepbound/cardiovascular-impact)
- [tirzepatide Does cigna cover Zepbound](https://healthrx.com/zepbound/cigna-coverage)
- [tirzepatide Zepbound cognitive function](https://healthrx.com/zepbound/cognition-impact)
- [tirzepatide Tirzepatide cost vs alternatives in class](https://healthrx.com/zepbound/cost-vs-alternatives)
- [tirzepatide How to stop Zepbound](https://healthrx.com/zepbound/discontinuation-protocol)
- [tirzepatide Zepbound drug interactions](https://healthrx.com/zepbound/drug-drug-interactions)
- [tirzepatide Zepbound evidence base](https://healthrx.com/zepbound/evidence-base-graded)
- [tirzepatide Vitamin D with Zepbound](https://healthrx.com/supplements-zepbound/with-vitamin-d)
- [tirzepatide Zepbound and progesterone HRT interaction](https://healthrx.com/interactions-zepbound/with-hrt-progesterone)
- [wegovy vs zepbound Wegovy vs Zepbound: Switching Between Them](https://healthrx.com/compare-glp-1/wegovy-vs-zepbound--switching)
- [zepbound vs rybelsus Zepbound vs Rybelsus](https://healthrx.com/compare-glp-1/zepbound-vs-rybelsus--switching)

![zepbound bone density: technologist positioning a DXA scanner over a clothed patient](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/zepbound/bone-health-impact.webp)

A DXA scan measures bone mineral density, which helps clinicians track skeletal health during significant weight loss. Full Zepbound bone health guide and sources at [healthrx.com/zepbound](https://healthrx.com/zepbound).

> Compounded drugs are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality before marketing.
